The majority of SLE patients recruited as part of this study had well controlled disease, which would support the notion that increased expression of soluble CD52 in these patients might reflect a homeostatic mechanism involved in improving or limiting their disease severity. Here, CD52 is linked to systemic lupus erythematosus.